DL - Lactic Acid
DrugTreated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
NCT Number: NCT01988558
The study objectives are to evaluate Tonsitin™ (10% Lactic Acid) safety, tolerability and preliminary efficacy, as a potent treatment for Recurrent Tonsillitis in children.
Looking for future studies?
Notify Me5 year–16 year
All sexes
Interventional
Phase 1 / Phase 2
Clalit Health Services, Pediatric Community Ambulatory Clinic, Petah Tikva, Israel
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
Placebo group to receive Raspberry flavored Syrup
Time frame: At 90 days post treatment
Time frame: Chnge from baseline at 6 months post treatment
Time frame: Chnge in medical history number of recurrent Tonsillitis episodes within 6 months post treatment
Time frame: Chnge from baseline at 90 days post treatment
Yali Pharmaceuticals
Industry
A Phase I/II, Randomized, Double Blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of DL-lactic Acid Syrup (Tonsitin) in Children With Recurrent Tonsillitis.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07235826
Infections, Otorhinolaryngologic Diseases
Urbino, PU (Pesaro E Urbino), Italy
View Trial DetailsNCT07675278
Chronic Tonsillitis, Infections
Rawalpindi, Punjab Province, Pakistan
View Trial DetailsNCT06326983
Anesthesia, Confusion
Waltham, Massachusetts, United States
View Trial DetailsNCT07457619
Infections, Otorhinolaryngologic Diseases
Bahawalpur, Pakistan
View Trial Details